deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04510285

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Esophageal Cancer Esophageal Neoplasms Esophageal Tumor Esophagogastric Tumors Gastric Cancer Gastric Tumor GastroEsophageal Cancer Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Cancer Gastroesophageal Junction Tumor
Interventions Pembrolizumab Trastuzumab
Updated 9 times since 2020 Last updated: Jan 5, 2023 Started: Aug 10, 2020 Primary completion: Dec 30, 2022 Completion: Dec 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of accrual

Other terminated trials from Memorial Sloan Kettering Cancer Center

See all terminations from Memorial Sloan Kettering Cancer Center

Other Esophageal Cancer trials with similar outcome

Browse all Esophageal Cancer trials

A PHASE2 clinical study on Esophageal Cancer and Esophageal Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 9 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotRecruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotRecruiting~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshotRecruiting~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshotRecruiting~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshotRecruiting~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshotTerminated~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Mar 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Feb 2023 — Mar 2023 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

▶ Show 4 earlier versions

  1. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  2. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations